TSHA Valuation

Taysha Gene Therapies Inc

Add to Watchlist

Advanced Chart

2.900

+0.06(2.113%)1D

Overview
Forecast
Valuation
Earnings

TSHA Relative Valuation

TSHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TSHA is overvalued; if below, it's undervalued.

Historical Valuation

Taysha Gene Therapies Inc (TSHA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 136.88 is considered Undervalued compared with the five-year average of -4.15. The fair price of Taysha Gene Therapies Inc (TSHA) is between 3.16 to 3.98 according to relative valuation methord. Compared to the current price of 2.86 USD , Taysha Gene Therapies Inc is Undervalued By 9.4%.

Relative Value

Fair Zone

3.16-3.98

Current Price：2.86

9.4%

Undervalued

-7.27

Trailing

Forward

-4.63

EV/EBITDA

Taysha Gene Therapies Inc. (TSHA) has a current EV/EBITDA of -4.63. The 5-year average EV/EBITDA is -3.69. The thresholds are as follows: Strongly Undervalued below -12.34, Undervalued between -12.34 and -8.01, Fairly Valued between 0.63 and -8.01, Overvalued between 0.63 and 4.95, and Strongly Overvalued above 4.95. The current Forward EV/EBITDA of -4.63 falls within the Historic Trend Line -Fairly Valued range.

-4.53

EV/EBIT

Taysha Gene Therapies Inc. (TSHA) has a current EV/EBIT of -4.53. The 5-year average EV/EBIT is -3.73. The thresholds are as follows: Strongly Undervalued below -11.87, Undervalued between -11.87 and -7.80, Fairly Valued between 0.34 and -7.80, Overvalued between 0.34 and 4.41, and Strongly Overvalued above 4.41. The current Forward EV/EBIT of -4.53 falls within the Historic Trend Line -Fairly Valued range.

136.88

Taysha Gene Therapies Inc. (TSHA) has a current PS of 136.88. The 5-year average PS is 29.85. The thresholds are as follows: Strongly Undervalued below -37.72, Undervalued between -37.72 and -3.94, Fairly Valued between 63.63 and -3.94, Overvalued between 63.63 and 97.41, and Strongly Overvalued above 97.41. The current Forward PS of 136.88 falls within the Strongly Overvalued range.

-8.50

P/OCF

Taysha Gene Therapies Inc. (TSHA) has a current P/OCF of -8.50. The 5-year average P/OCF is -6.57. The thresholds are as follows: Strongly Undervalued below -25.31, Undervalued between -25.31 and -15.94, Fairly Valued between 2.80 and -15.94, Overvalued between 2.80 and 12.17, and Strongly Overvalued above 12.17. The current Forward P/OCF of -8.50 falls within the Historic Trend Line -Fairly Valued range.

-8.50

P/FCF

Taysha Gene Therapies Inc. (TSHA) has a current P/FCF of -8.50. The 5-year average P/FCF is -5.31. The thresholds are as follows: Strongly Undervalued below -14.87, Undervalued between -14.87 and -10.09, Fairly Valued between -0.53 and -10.09, Overvalued between -0.53 and 4.25, and Strongly Overvalued above 4.25. The current Forward P/FCF of -8.50 falls within the Historic Trend Line -Fairly Valued range.

Taysha Gene Therapies Inc (TSHA) has a current Price-to-Book (P/B) ratio of 3.11. Compared to its 3-year average P/B ratio of 9.82 , the current P/B ratio is approximately -68.28% higher. Relative to its 5-year average P/B ratio of -88.97, the current P/B ratio is about -103.50% higher. Taysha Gene Therapies Inc (TSHA) has a Forward Free Cash Flow (FCF) yield of approximately -10.36%. Compared to its 3-year average FCF yield of -63.52%, the current FCF yield is approximately -83.69% lower. Relative to its 5-year average FCF yield of -52.05% , the current FCF yield is about -80.09% lower.

3.11

P/B

Median3y

9.82

Median5y

-88.97

-10.36

FCF Yield

Median3y

-63.52

Median5y

-52.05

Competitors Valuation Multiple

The average P/S ratio for TSHA's competitors is 494.02, providing a benchmark for relative valuation. Taysha Gene Therapies Inc Corp (TSHA) exhibits a P/S ratio of 136.88, which is -72.29% above the industry average. Given its robust revenue growth of 78.60%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TSHA.O

Taysha Gene Therapies Inc

Sana Biotechnology Inc

Loss

737.84M

IOVA.O

Iovance Biotherapeutics Inc

Anavex Life Sciences Corp

Loss

815.13M

DNTH.O

Dianthus Therapeutics Inc

421.32

-89.64%

780.89M

Performance Decomposition

Market capitalization of TSHA increased by 41.29% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.11M to 1.99M.

The secondary factor is the P/E Change, contributed -9.23%to the performance.

Overall, the performance of TSHA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

78.60%

1.11M → 1.99M

Revenue Growth

-28.08%

-1.88K → -1.35K

Margin Expansion

-9.23%

-9.31 → -8.45

P/E Change

41.29%